Drugs / racemic leucovorin
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02468557 Background | Jul 2015 → Apr 2016 | pancreatic ductal adenocarcinoma | Gilead Sciences | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | racemic leucovorin | “This regimen consists of levoleucovorin 200 milligram/meter per square (mg/m\^2) or racemic leucovorin 400 mg/m\^2, oxaliplatin 85 mg/m\^2, bolus 5-fluorouracil 400 mg/m\^2,...” NCT02468557 ↗ |
| Route | Intravenous | “mFOLFOX6 will be administered intravenously on Days 1 and 15 of each 28 day cycle.” NCT02468557 ↗ |